Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Pipeline Review, H2 2016’, provides in depth analysis on Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted pipeline therapeutics.

The report provides comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)

The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects

The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Neurimmune Holding AG

Nordic Bioscience A/S

Novo Nordisk A/S

reMYND NV

Zealand Pharma A/S

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Overview 7

Therapeutics Development 8

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Products under Development by Stage of Development 8

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Products under Development by Therapy Area 9

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Products under Development by Indication 10

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Products Glance 11

Early Stage Products 11

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Products under Development by Companies 12

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Products under Development by Universities/Institutes 14

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development 23

AstraZeneca Plc 23

Neurimmune Holding AG 24

Nordic Bioscience A/S 25

Novo Nordisk A/S 26

reMYND NV 27

Zealand Pharma A/S 28

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles 29

(insulin human + pramlintide acetate) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AM-833 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

KBP-042 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

KBP-056 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NI-203 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ReS-13I - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ReS-39I - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Salmon Calcitonin - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

UGP-302 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ZP-4982 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Projects 43

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products 44

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Featured News & Press Releases 45

Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions 45

May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models 45

Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by AstraZeneca Plc, H2 2016 23

Pipeline by Neurimmune Holding AG, H2 2016 24

Pipeline by Nordic Bioscience A/S, H2 2016 25

Pipeline by Novo Nordisk A/S, H2 2016 26

Pipeline by reMYND NV, H2 2016 27

Pipeline by Zealand Pharma A/S, H2 2016 28

Dormant Projects, H2 2016 43

Discontinued Products, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports